Acrigen Biosciences Email Format
Biotechnology ResearchCalifornia, United States2-10 Employees
Acrigen Biosciences is a California-based biotechnology company focused on developing gene-editing therapies for genetic disorders. It pursues a precision editing approach that blends CRISPR-based editors with anti-CRISPR proteins to enhance the precision, efficacy, and safety of genetic medicines. The company was founded in 2019 by Dr. Joseph Bondy-Denomy, an Associate Professor at UCSF and discoverer of anti-CRISPR proteins, together with Dr. David Rabuka, a former founder and CSO of Redwood Biosciences. It is focused on translating this technology into a pipeline of therapies intended for clinical development, within the biotechnology research sector. Based in California, Acrigen Biosciences operates as a small team aimed at advancing precision genetic therapies to the clinic.